Kai Adachi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kai Adachi has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Kosuke Okuwaki
Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan
14 shared publications - Masafumi Watanabe
Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan
13 shared publications - Akihiro Tamaki
Department of Gastroenterology Kitasato University School of Medicine Sagamihara Kanagawa Japan
9 shared publications - Taro Hanaoka
Department of Gastroenterology Kitasato University School of Medicine Sagamihara Kanagawa Japan
9 shared publications - Chika Kusano
Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan
8 shared publications - Hiroshi Imaizumi
Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan
8 shared publications
Latest Publications
- Open Access
Evaluating a Modified American Society of Anesthesiologists Physical Status‐Based Sedation Management System for Pancreatobiliary Endoscopy: A Prospective Feasibility Study
Objectives: To prospectively evaluate the feasibility of implementing a modified American Society of Anesthesiologists Physical Status (ASA‐PS)‐based sedation management system for endoscopist‐managed sedation in pancreatobiliary endoscopy. Methods: This single‐center, single‐arm prospective feasibility study involved 2000 patients (2024–2025). Sedation risk was stratified using a modified ASA‐PS classification system combined with predefined high‐risk clinical factors (severe obesity, obstructive sleep apnea requiring continuous positive airway pressure, chronic obstructive pulmonary disease requiring home oxygen therapy, reduced functional capacity, and difficult sedation history). Patients meeting high‐risk criteria underwent pre‐procedural anesthesiologist assessment to determine sedation providers. The primary outcome was sedation‐related adverse event (SRAE) incidence during endoscopist‐managed sedation. The secondary outcomes were the sedation success rate and SRAE‐associated risk factors. Results: Among 2000 patients, 231 (11.6%) were classified as having high risk for sedation. Post‐assessment, anesthesiologists and endoscopists managed sedation for 86 (4.3%) and 1914 (95.7%) patients, respectively. In the endoscopist‐managed group, SRAEs occurred in 63 patients (3.3%), corresponding to a success rate of 96.7%. No patient required tracheal intubation or conversion to general anesthesia. In multivariable analysis, endoscopic ultrasonography‐guided sampling was independently associated with reduced SRAEs (odds ratio 0.407, 95% confidence interval 0.184–0.899; p = 0.026); no independent predictors of increased SRAEs were identified. Conclusions: The modified ASA‐PS‐based sedation management system may be a feasible approach in settings with limited anesthesiology resources, warranting further validation. Trial Registration: UMIN000053211
Open AccessEvaluating a Modified American Society of Anesthesiologists Physical Status‐Based Sedation Management System for Pancreatobiliary Endoscopy: A Prospective Feasibility Study
Objectives: To prospectively evaluate the feasibility of implementing a modified American Society of Anesthesiologists Physical Status (ASA‐PS)‐based sedation management system for endoscopist‐managed sedation in pancreatobiliary endoscopy. Methods: This single‐center, single‐arm prospective feasibility study involved 2000 patients (2024–2025). Sedation risk was stratified using a modified ASA‐PS classification system combined with predefined high‐risk clinical factors (severe obesity, obstructive sleep apnea requiring continuous positive airway pressure, chronic obstructive pulmonary disease requiring home oxygen therapy, reduced functional capacity, and difficult sedation history). Patients meeting high‐risk criteria underwent pre‐procedural anesthesiologist assessment to determine sedation providers. The primary outcome was sedation‐related adverse event (SRAE) incidence during endoscopist‐managed sedation. The secondary outcomes were the sedation success rate and SRAE‐associated risk factors. Results: Among 2000 patients, 231 (11.6%) were classified as having high risk for sedation. Post‐assessment, anesthesiologists and endoscopists managed sedation for 86 (4.3%) and 1914 (95.7%) patients, respectively. In the endoscopist‐managed group, SRAEs occurred in 63 patients (3.3%), corresponding to a success rate of 96.7%. No patient required tracheal intubation or conversion to general anesthesia. In multivariable analysis, endoscopic ultrasonography‐guided sampling was independently associated with reduced SRAEs (odds ratio 0.407, 95% confidence interval 0.184–0.899; p = 0.026); no independent predictors of increased SRAEs were identified. Conclusions: The modified ASA‐PS‐based sedation management system may be a feasible approach in settings with limited anesthesiology resources, warranting further validation. Trial Registration: UMIN000053211
- 23 August 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (10) , 3262-3263
Reply to Comment on Randomized Controlled Trial of Endoscopic Ultrasound‐Guided Liver Biopsy Versus Percutaneous Liver Biopsy for Obtaining Histologically Adequate Specimens
- 23 August 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (10) , 3262-3263
Reply to Comment on Randomized Controlled Trial of Endoscopic Ultrasound‐Guided Liver Biopsy Versus Percutaneous Liver Biopsy for Obtaining Histologically Adequate Specimens
- 4 August 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (9) , 3062-3063
Reply to “Methodological Concerns Regarding the Primary Endpoint and External Validity in the Randomized Trial of EUS‐Guided Versus Percutaneous Liver Biopsy”
- 4 August 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (9) , 3062-3063
Reply to “Methodological Concerns Regarding the Primary Endpoint and External Validity in the Randomized Trial of EUS‐Guided Versus Percutaneous Liver Biopsy”
- Open Access
- 16 July 2026
- Published by Georg Thieme Verlag KG in Journal of Digestive Endoscopy
Incidence of Cholecystitis after Multihole Fully Covered Metal Stent Placement for Unresectable Malignant Distal Biliary Obstruction: A Prospective Exploratory Study
Cholecystitis and stent migration are adverse events of fully covered self-expandable metal stents (SEMS) for malignant distal biliary obstruction. The aim of this study was to evaluate the incidence of cholecystitis, clinical outcomes, and safety of a multihole fully covered SEMS (MHSEMS) in unresectable malignant distal biliary obstruction. This single-center, prospective, exploratory study included consecutive patients who underwent MHSEMS placement for unresectable malignant distal biliary obstruction between June 2023 and January 2024. The primary endpoint was the incidence of cholecystitis. Stent patency was analyzed using the Kaplan–Meier method, and categorical variables were expressed as percentages. Twenty patients were enrolled, and all were followed for up to 1 year or until death; technical and clinical success rates were both 100%. No cholecystitis occurred despite the presence of reported risk factors for cholecystitis: cholelithiasis or sludge (65%), contrast filling of the gallbladder (35%), and tumor involvement of the cystic duct (15%). Recurrent biliary obstruction occurred in six patients (30%): two stent migrations, three occlusions, and one biliary kinking. All recurrent biliary obstruction cases were managed endoscopically. Median time to recurrent biliary obstruction was not reached. One-year stent patency rate was 62%. Adverse events other than recurrent biliary obstruction were mild. No cholecystitis occurred after MHSEMS placement in this small prospective cohort, suggesting a favorable safety profile; however, larger comparative studies are needed to clarify its effect. UMIN000051182; registered June 1, 2023.
- 16 July 2026
- Published by Georg Thieme Verlag KG in Journal of Digestive Endoscopy
Open AccessIncidence of Cholecystitis after Multihole Fully Covered Metal Stent Placement for Unresectable Malignant Distal Biliary Obstruction: A Prospective Exploratory Study
Cholecystitis and stent migration are adverse events of fully covered self-expandable metal stents (SEMS) for malignant distal biliary obstruction. The aim of this study was to evaluate the incidence of cholecystitis, clinical outcomes, and safety of a multihole fully covered SEMS (MHSEMS) in unresectable malignant distal biliary obstruction. This single-center, prospective, exploratory study included consecutive patients who underwent MHSEMS placement for unresectable malignant distal biliary obstruction between June 2023 and January 2024. The primary endpoint was the incidence of cholecystitis. Stent patency was analyzed using the Kaplan–Meier method, and categorical variables were expressed as percentages. Twenty patients were enrolled, and all were followed for up to 1 year or until death; technical and clinical success rates were both 100%. No cholecystitis occurred despite the presence of reported risk factors for cholecystitis: cholelithiasis or sludge (65%), contrast filling of the gallbladder (35%), and tumor involvement of the cystic duct (15%). Recurrent biliary obstruction occurred in six patients (30%): two stent migrations, three occlusions, and one biliary kinking. All recurrent biliary obstruction cases were managed endoscopically. Median time to recurrent biliary obstruction was not reached. One-year stent patency rate was 62%. Adverse events other than recurrent biliary obstruction were mild. No cholecystitis occurred after MHSEMS placement in this small prospective cohort, suggesting a favorable safety profile; however, larger comparative studies are needed to clarify its effect. UMIN000051182; registered June 1, 2023.
- Top Cited Papers
- 17 May 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
Randomized Controlled Trial of Endoscopic Ultrasound‐Guided Liver Biopsy Versus Percutaneous Liver Biopsy for Obtaining Histologically Adequate Specimens
Aim: To compare endoscopic ultrasound‐guided liver biopsy (EUS‐LB) with percutaneous liver biopsy (P‐LB) in terms of histological adequacy, safety, and patient‐reported pain in parenchymal liver disease. Methods: In this single‐center randomized controlled trial, 80 patients were assigned to either EUS‐LB ( n = 41) or P‐LB ( n = 39). The primary endpoint was histological adequacy, defined as total specimen length (TSL) ≥ 15 mm and ≥ 6 complete portal tracts (CPTs). The main secondary endpoints were the definitive histological diagnostic rate, specimen characteristics (CPTs, TSL, and longest specimen length), patient‐reported pain, and procedure‐related adverse events (AEs). EUS‐LB employed a 19‐gauge Franseen‐tip needle with wet suction under conscious sedation, whereas P‐LB used a 16‐gauge Tru‐Cut needle under local anesthesia. Results: Histological adequacy based on predefined histologic criteria was achieved more frequently with EUS‐LB than with P‐LB (70.7% vs. 10.3%; difference, 60.4%; 95% CI 43.5–77.3). The definitive histological diagnostic rates were similar (92.7% vs. 97.4%). The median TSL was longer with EUS‐LB (20.0 vs. 12.8 mm), whereas ≥ 6 CPTs were more common with P‐LB (97.4% vs. 80.5%). AEs occurred in 2.4% versus 25.6%, driven in the P‐LB arm by procedural stress–related hemodynamic responses (transient grade III hypertension); patient‐reported pain favored EUS‐LB (no pain during the procedure, 95.1% vs. 30.8%). No serious AEs or bleeding events occurred, and none required prolonged hospitalization. Conclusions: EUS‐LB met the noninferiority criterion for histologic adequacy and achieved a diagnostic performance comparable to that of P‐LB with lower patient‐reported pain. EUS‐LB may be a reasonable alternative when endoscopic expertise and sedation are available.
- 17 May 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
Top Cited PapersRandomized Controlled Trial of Endoscopic Ultrasound‐Guided Liver Biopsy Versus Percutaneous Liver Biopsy for Obtaining Histologically Adequate Specimens
Aim: To compare endoscopic ultrasound‐guided liver biopsy (EUS‐LB) with percutaneous liver biopsy (P‐LB) in terms of histological adequacy, safety, and patient‐reported pain in parenchymal liver disease. Methods: In this single‐center randomized controlled trial, 80 patients were assigned to either EUS‐LB ( n = 41) or P‐LB ( n = 39). The primary endpoint was histological adequacy, defined as total specimen length (TSL) ≥ 15 mm and ≥ 6 complete portal tracts (CPTs). The main secondary endpoints were the definitive histological diagnostic rate, specimen characteristics (CPTs, TSL, and longest specimen length), patient‐reported pain, and procedure‐related adverse events (AEs). EUS‐LB employed a 19‐gauge Franseen‐tip needle with wet suction under conscious sedation, whereas P‐LB used a 16‐gauge Tru‐Cut needle under local anesthesia. Results: Histological adequacy based on predefined histologic criteria was achieved more frequently with EUS‐LB than with P‐LB (70.7% vs. 10.3%; difference, 60.4%; 95% CI 43.5–77.3). The definitive histological diagnostic rates were similar (92.7% vs. 97.4%). The median TSL was longer with EUS‐LB (20.0 vs. 12.8 mm), whereas ≥ 6 CPTs were more common with P‐LB (97.4% vs. 80.5%). AEs occurred in 2.4% versus 25.6%, driven in the P‐LB arm by procedural stress–related hemodynamic responses (transient grade III hypertension); patient‐reported pain favored EUS‐LB (no pain during the procedure, 95.1% vs. 30.8%). No serious AEs or bleeding events occurred, and none required prolonged hospitalization. Conclusions: EUS‐LB met the noninferiority criterion for histologic adequacy and achieved a diagnostic performance comparable to that of P‐LB with lower patient‐reported pain. EUS‐LB may be a reasonable alternative when endoscopic expertise and sedation are available.
- Open Access
- 30 March 2026
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 59 (2) , 273-279
Feasibility of primary precut sphincterotomy in endoscopic retrograde cholangiopancreatography for patients with large oral protrusions of the duodenal papilla; prospective observation study in Japan
Background/Aims: Large oral protrusions may increase the difficulty of biliary cannulation in endoscopic retrograde cholangiopancreatography (ERCP) and often require precut sphincterotomy. Precut sphincterotomy is a risk factor for post-ERCP pancreatitis (PEP). However, this may be reduced by a primary precut sphincterotomy. This study aimed to evaluate the results of biliary cannulation after primary precut sphincterotomy in patients with large oral protrusions identified during ERCP.Methods: In this prospective observation study, we included 38 patients with naïve papillae who underwent ERCPs between January 2021 and December 2022 that revealed large oral protrusions and who underwent primary precut sphincterotomies as the biliary cannulation method. Primary precut sphincterotomy was performed by an experienced endoscopist in all cases.Results: The biliary cannulation success rate for primary precut sphincterotomies was 100% (38/38 patients). There were seven cases (18.4%) of ERCP-related adverse events, specifically bleeding. Of these, six (15.8%) were mild and one (2.6%) was moderate. No cases of PEP were observed.Conclusions: Primary precut sphincterotomy for large oral protrusions performed by an experienced endoscopist had a high biliary cannulation success rate without the occurrence of PEP. This procedure can be used for biliary cannulation in patients with large oral protrusions (University Hospital Medical Information Network-Clinical Trials Registry number: UMIN000042805).
- 30 March 2026
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 59 (2) , 273-279
Open AccessFeasibility of primary precut sphincterotomy in endoscopic retrograde cholangiopancreatography for patients with large oral protrusions of the duodenal papilla; prospective observation study in Japan
Background/Aims: Large oral protrusions may increase the difficulty of biliary cannulation in endoscopic retrograde cholangiopancreatography (ERCP) and often require precut sphincterotomy. Precut sphincterotomy is a risk factor for post-ERCP pancreatitis (PEP). However, this may be reduced by a primary precut sphincterotomy. This study aimed to evaluate the results of biliary cannulation after primary precut sphincterotomy in patients with large oral protrusions identified during ERCP.Methods: In this prospective observation study, we included 38 patients with naïve papillae who underwent ERCPs between January 2021 and December 2022 that revealed large oral protrusions and who underwent primary precut sphincterotomies as the biliary cannulation method. Primary precut sphincterotomy was performed by an experienced endoscopist in all cases.Results: The biliary cannulation success rate for primary precut sphincterotomies was 100% (38/38 patients). There were seven cases (18.4%) of ERCP-related adverse events, specifically bleeding. Of these, six (15.8%) were mild and one (2.6%) was moderate. No cases of PEP were observed.Conclusions: Primary precut sphincterotomy for large oral protrusions performed by an experienced endoscopist had a high biliary cannulation success rate without the occurrence of PEP. This procedure can be used for biliary cannulation in patients with large oral protrusions (University Hospital Medical Information Network-Clinical Trials Registry number: UMIN000042805).
- Open Access
Efficacy and Safety of a 6‐Month Placement of a Fully Covered Self‐Expanding Metal Stent for Refractory or Recurrent Hepaticojejunostomy Anastomotic Stricture via Balloon Enteroscopy‐Assisted Endoscopic Retrograde Cholangiopancreatography
Objectives: Balloon enteroscopy‐assisted endoscopic retrograde cholangiopancreatography (BE‐assisted ERCP) is performed for hepaticojejunostomy anastomotic stricture (HJAS) after biliary‐enteric anastomosis. Although endoscopic balloon dilation (EBD) and plastic stent (PS) placement are commonly performed, they result in high recurrence rates. Studies have demonstrated the efficacy of fully covered self‐expanding metal stents (FCSEMS) in HJAS management; however, none have systematically evaluated the outcomes of 6‐month placement. Therefore, this retrospective study aimed to evaluate the efficacy and safety of a 6‐month FCSEMS placement for benign refractory or recurrent HJAS. Methods: We evaluated patients who underwent initial treatment with EBD alone or EBD plus PS placement via BE‐assisted ERCP between April 2015 and March 2024. Among them, patients with refractory or recurrent HJAS received 6‐month FCSEMS placements. The study outcomes were HJAS resolution, adverse events (AEs), and recurrence rates. Results: Among 92 patients who underwent initial EBD alone or EBD with PS placement, the HJAS resolution rate was 90.2%. The median follow‐up period after the initial treatment was 16.1 months, with recurrence observed in 48.2% of patients. Among the 34 patients with refractory or recurrent HJAS, FCSEMS placement achieved a resolution rate of 97.1% in a median of 182 days. AEs occurred in 14.7% of patients (moderate, n = 3; mild, n = 2) following FCSEMS placement. During a median follow‐up of 30.9 months, no recurrence was observed after HJAS resolution using FCSEMS. Conclusions: The 6‐month FCSEMS placement for refractory or recurrent HJAS showed high efficacy and safety, indicating its potential as a preferred treatment option.
Open AccessEfficacy and Safety of a 6‐Month Placement of a Fully Covered Self‐Expanding Metal Stent for Refractory or Recurrent Hepaticojejunostomy Anastomotic Stricture via Balloon Enteroscopy‐Assisted Endoscopic Retrograde Cholangiopancreatography
Objectives: Balloon enteroscopy‐assisted endoscopic retrograde cholangiopancreatography (BE‐assisted ERCP) is performed for hepaticojejunostomy anastomotic stricture (HJAS) after biliary‐enteric anastomosis. Although endoscopic balloon dilation (EBD) and plastic stent (PS) placement are commonly performed, they result in high recurrence rates. Studies have demonstrated the efficacy of fully covered self‐expanding metal stents (FCSEMS) in HJAS management; however, none have systematically evaluated the outcomes of 6‐month placement. Therefore, this retrospective study aimed to evaluate the efficacy and safety of a 6‐month FCSEMS placement for benign refractory or recurrent HJAS. Methods: We evaluated patients who underwent initial treatment with EBD alone or EBD plus PS placement via BE‐assisted ERCP between April 2015 and March 2024. Among them, patients with refractory or recurrent HJAS received 6‐month FCSEMS placements. The study outcomes were HJAS resolution, adverse events (AEs), and recurrence rates. Results: Among 92 patients who underwent initial EBD alone or EBD with PS placement, the HJAS resolution rate was 90.2%. The median follow‐up period after the initial treatment was 16.1 months, with recurrence observed in 48.2% of patients. Among the 34 patients with refractory or recurrent HJAS, FCSEMS placement achieved a resolution rate of 97.1% in a median of 182 days. AEs occurred in 14.7% of patients (moderate, n = 3; mild, n = 2) following FCSEMS placement. During a median follow‐up of 30.9 months, no recurrence was observed after HJAS resolution using FCSEMS. Conclusions: The 6‐month FCSEMS placement for refractory or recurrent HJAS showed high efficacy and safety, indicating its potential as a preferred treatment option.
- Open Access
- 30 November 2024
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 57 (6) , 807-813
Effectiveness of endoscopic ultrasound-guided tissue acquisition with stereomicroscopic on-site evaluation for preoperative diagnosis of resectable or borderline resectable pancreatic cancer: a prospective study
Background/Aims: To validate endoscopic ultrasound-guided tissue acquisition (EUS-TA) used in conjunction with stereomicroscopic on-site evaluation (SOSE) as a preoperative diagnostic tool for resectable pancreatic cancer (R-PC) and borderline resectable PC (BR-PC).Methods: Seventy-eight consecutive patients who underwent EUS-TA for suspected R-PC or BR-PC were enrolled. The primary endpoint was the sensitivity of EUS-TA together with SOSE based on the stereomicroscopically visible white core (SVWC) cutoff value. One or two sites were punctured by using a 22-gauge biopsy needle for EUS-TA, based on the SOSE findings.Results: We collected 99 specimens from 56 and 22 patients with R-PC and BR-PC, respectively. Based on the SOSE results, we performed 57 procedures with one puncture. The SVWC cutoff values were met in 73.7% and 73.1% of all specimens and in those obtained during the first puncture, respectively. The final diagnoses were malignant and benign tumors in 76 and two patients, respectively. The overall sensitivity, specificity, and accuracy of EUS-TA for the 78 lesions were 90.8%, 100%, and 91.0%, respectively. The sensitivity for malignant diagnosis based on the SVWC cutoff value were 89.5% and 90.4% for the first puncture and all specimens, respectively.Conclusions: The sensitivity of EUS-TA in conjunction with SOSE for malignancy diagnosis in patients with suspected R-PC or BR-PC was 90.4%.
- 30 November 2024
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 57 (6) , 807-813
Open AccessEffectiveness of endoscopic ultrasound-guided tissue acquisition with stereomicroscopic on-site evaluation for preoperative diagnosis of resectable or borderline resectable pancreatic cancer: a prospective study
Background/Aims: To validate endoscopic ultrasound-guided tissue acquisition (EUS-TA) used in conjunction with stereomicroscopic on-site evaluation (SOSE) as a preoperative diagnostic tool for resectable pancreatic cancer (R-PC) and borderline resectable PC (BR-PC).Methods: Seventy-eight consecutive patients who underwent EUS-TA for suspected R-PC or BR-PC were enrolled. The primary endpoint was the sensitivity of EUS-TA together with SOSE based on the stereomicroscopically visible white core (SVWC) cutoff value. One or two sites were punctured by using a 22-gauge biopsy needle for EUS-TA, based on the SOSE findings.Results: We collected 99 specimens from 56 and 22 patients with R-PC and BR-PC, respectively. Based on the SOSE results, we performed 57 procedures with one puncture. The SVWC cutoff values were met in 73.7% and 73.1% of all specimens and in those obtained during the first puncture, respectively. The final diagnoses were malignant and benign tumors in 76 and two patients, respectively. The overall sensitivity, specificity, and accuracy of EUS-TA for the 78 lesions were 90.8%, 100%, and 91.0%, respectively. The sensitivity for malignant diagnosis based on the SVWC cutoff value were 89.5% and 90.4% for the first puncture and all specimens, respectively.Conclusions: The sensitivity of EUS-TA in conjunction with SOSE for malignancy diagnosis in patients with suspected R-PC or BR-PC was 90.4%.
- 15 May 2024
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 69 (7) , 2567-2572
Endoscopic Ultrasound-Guided Tissue Acquisition Using Fork-Tip Needle for Subepithelial Lesions: A Single-Center Validation Study
Background The cutoff value for stereomicroscopic on-site evaluation (SOSE) in endoscopic ultrasound-guided tissue acquisition (EUS-TA) has high diagnostic sensitivity when a Franseen needle is employed for upper gastrointestinal subepithelial lesions (SELs) (stereomicroscopically visible white core [SVWC] ≥ 4 mm). Aim We aimed to determine whether high diagnostic sensitivity could be obtained when EUS-TA was performed using a Fork-tip needle. Methods Twenty-one patients were prospectively registered. Patients underwent EUS-TA using a Fork-tip needle for upper gastrointestinal SELs at Kitasato University Hospital between January and November 2022. Punctures were made twice using the needle, and SOSE was conducted for each specimen. Blood and physical examination were performed to assess adverse events. Pathological diagnosis was made using hematoxylin and eosin-stained sections and immunohistochemical staining. Statistical comparisons were completed using Fisher’s exact tests. Results The diagnostic rate of EUS-TA was 100% (21/21 cases). The final diagnosis was gastrointestinal stromal tumor in 17 (81.0%) and leiomyoma in 4 (19.0%) patients. SOSE was conducted on all 42 punctures, and the tissue sampling rate was 100% (42/42 punctures). Specimens with SVWC ≥ 4 mm were collected in 97.6% punctures (41/42 punctures) and the diagnostic sensitivity for these specimens was 100% (41/41 punctures), which is significantly higher (p < 0.0238) compared to the absence of cutoff value (diagnostic sensitivity of 0%). No EUS-TA-related adverse events occurred. Conclusions EUS-TA combined with SOSE for upper gastrointestinal SEL using a fork-tip needle had a high diagnostic rate, and the cutoff value of SVWC ≥ 4 mm had high diagnostic sensitivity.
- 15 May 2024
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 69 (7) , 2567-2572
Endoscopic Ultrasound-Guided Tissue Acquisition Using Fork-Tip Needle for Subepithelial Lesions: A Single-Center Validation Study
Background The cutoff value for stereomicroscopic on-site evaluation (SOSE) in endoscopic ultrasound-guided tissue acquisition (EUS-TA) has high diagnostic sensitivity when a Franseen needle is employed for upper gastrointestinal subepithelial lesions (SELs) (stereomicroscopically visible white core [SVWC] ≥ 4 mm). Aim We aimed to determine whether high diagnostic sensitivity could be obtained when EUS-TA was performed using a Fork-tip needle. Methods Twenty-one patients were prospectively registered. Patients underwent EUS-TA using a Fork-tip needle for upper gastrointestinal SELs at Kitasato University Hospital between January and November 2022. Punctures were made twice using the needle, and SOSE was conducted for each specimen. Blood and physical examination were performed to assess adverse events. Pathological diagnosis was made using hematoxylin and eosin-stained sections and immunohistochemical staining. Statistical comparisons were completed using Fisher’s exact tests. Results The diagnostic rate of EUS-TA was 100% (21/21 cases). The final diagnosis was gastrointestinal stromal tumor in 17 (81.0%) and leiomyoma in 4 (19.0%) patients. SOSE was conducted on all 42 punctures, and the tissue sampling rate was 100% (42/42 punctures). Specimens with SVWC ≥ 4 mm were collected in 97.6% punctures (41/42 punctures) and the diagnostic sensitivity for these specimens was 100% (41/41 punctures), which is significantly higher (p < 0.0238) compared to the absence of cutoff value (diagnostic sensitivity of 0%). No EUS-TA-related adverse events occurred. Conclusions EUS-TA combined with SOSE for upper gastrointestinal SEL using a fork-tip needle had a high diagnostic rate, and the cutoff value of SVWC ≥ 4 mm had high diagnostic sensitivity.
- 16 January 2024
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 39 (4) , 740-745
Efficacy of endoscopic ultrasound‐guided tissue acquisition using stereo‐microscopic on‐site evaluation for possible comprehensive genome profile in patients with advanced pancreatic cancer
Background and Aim: Stereomicroscopic on‐site evaluation (SOSE) is a rapid evaluation method for endoscopic ultrasound‐guided tissue acquisition (EUS‐TA) with a high diagnostic sensitivity when the stereomicroscopically visible white core (SVWC) cut‐off value (≥ 11 mm) is met. We prospectively examined the association between SVWCs and the adequacy of tissue specimens, assuming subsequent comprehensive genome profiling (CGP).Methods: This study included 66 consecutive patients with suspected unresectable pancreatic cancer who underwent EUS‐TA. The primary endpoint was the frequency of combined samples with ≥ 20% tumor cell content that met over twice the SVWC (T‐SVWC) cut‐off value, achieved through multiple punctures. The secondary endpoints were the number of punctures, the percentage of SVWC cut‐off values, adverse events, the positive diagnosis rate, and the tissue section area.Results: The median number of EUS‐TA punctures for suspected unresectable pancreatic cancer was 3 (range, 3–4); SVWC and T‐SVWC cut‐off values were obtained in 171/206 specimens and 65/66 patients, respectively. There were no EUS‐TA‐related adverse events. The positive diagnosis rate of EUS‐TA was 95.5%. Among the 63 patients meeting the T‐SVWC cut‐off value in pathological diagnoses, the median tumor cell content was 40% (range, 5–80%), with 57 patients having tumor cell content ≥ 20%. The median tissue section area was 15 (range, 3–40) mm2.Conclusions: When performing EUS‐TA for unresectable pancreatic cancer with the intention of subsequent CGP, obtaining a high tumor cell content (≥ 20%) by assessing the T‐SVWC cut‐off value via SOSE may serve as a novel indicator for on‐site estimation of CGP suitability for EUS‐TA specimens.
- 16 January 2024
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 39 (4) , 740-745
Efficacy of endoscopic ultrasound‐guided tissue acquisition using stereo‐microscopic on‐site evaluation for possible comprehensive genome profile in patients with advanced pancreatic cancer
Background and Aim: Stereomicroscopic on‐site evaluation (SOSE) is a rapid evaluation method for endoscopic ultrasound‐guided tissue acquisition (EUS‐TA) with a high diagnostic sensitivity when the stereomicroscopically visible white core (SVWC) cut‐off value (≥ 11 mm) is met. We prospectively examined the association between SVWCs and the adequacy of tissue specimens, assuming subsequent comprehensive genome profiling (CGP).Methods: This study included 66 consecutive patients with suspected unresectable pancreatic cancer who underwent EUS‐TA. The primary endpoint was the frequency of combined samples with ≥ 20% tumor cell content that met over twice the SVWC (T‐SVWC) cut‐off value, achieved through multiple punctures. The secondary endpoints were the number of punctures, the percentage of SVWC cut‐off values, adverse events, the positive diagnosis rate, and the tissue section area.Results: The median number of EUS‐TA punctures for suspected unresectable pancreatic cancer was 3 (range, 3–4); SVWC and T‐SVWC cut‐off values were obtained in 171/206 specimens and 65/66 patients, respectively. There were no EUS‐TA‐related adverse events. The positive diagnosis rate of EUS‐TA was 95.5%. Among the 63 patients meeting the T‐SVWC cut‐off value in pathological diagnoses, the median tumor cell content was 40% (range, 5–80%), with 57 patients having tumor cell content ≥ 20%. The median tissue section area was 15 (range, 3–40) mm2.Conclusions: When performing EUS‐TA for unresectable pancreatic cancer with the intention of subsequent CGP, obtaining a high tumor cell content (≥ 20%) by assessing the T‐SVWC cut‐off value via SOSE may serve as a novel indicator for on‐site estimation of CGP suitability for EUS‐TA specimens.